Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer

This study provides evidence that real-world changes in aCT recommendations due to the 12-gene assay are likely to reduce direct medical costs and improve well-being for stage II, T3, MMR-P colon cancer patients. </AbstractSection> Copyright The Author(s) 2014

MoreLess

Year of publication:	2014
Authors:	Alberts, Steven ; Yu, Tiffany ; Behrens, Robert ; Renfro, Lindsay ; Srivastava, Geetika ; Soori, Gamini ; Dakhil, Shaker ; Mowat, Rex ; Kuebler, John ; Kim, George ; Mazurczak, Miroslaw ; Hornberger, John
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 32.2014, 12, p. 1231-1243
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011152269